XML 6 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Cover
Apr. 30, 2025
Cover [Abstract]  
Document Type 8-K/A
Amendment Flag true
Amendment Description We previously reported that between April 30, 2025 and May 9, 2025, the Company sold an aggregate of 1,030,413 shares (the “Shares”) of its Common Stock to 22 Non-U.S. Persons (as defined in Regulation S under the Securities Act. The offer and sale of the Shares was exempt from the registration provisions of the Securities Act, pursuant to Regulation S thereunder (“Regulation S”); the Company received aggregate gross proceeds of approximately $619,625 for the Shares (the “Reg S Offering”). The Reg S Offering was conducted pursuant to a Securities Purchase Agreement with each investor, who also entered into a Voting Rights Proxy Agreement, pursuant to which each purchaser agreed to transfer all of his/her voting rights to Eugene Jiang, the Company’s chairman for the maximum time permitted by law.
Document Period End Date Apr. 30, 2025
Entity File Number 001-40700
Entity Registrant Name ABVC BIOPHARMA, INC.
Entity Central Index Key 0001173313
Entity Tax Identification Number 26-0014658
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 44370 Old Warm Springs Blvd.
Entity Address, City or Town Fremont
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94538
City Area Code (510)
Local Phone Number 668-0881
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ABVC
Security Exchange Name NASDAQ
Entity Emerging Growth Company false